[{"id":"8f2eeb60-09f0-4084-b1ee-ab86329273ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT04485052","created_at":"2022-04-24T09:02:43.518Z","updated_at":"2024-07-02T16:35:32.242Z","phase":"Phase 1/2","brief_title":"Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04485052","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • decitabine • letaplimab (IBI188)"],"overall_status":"Suspended","enrollment":" Enrollment 222","initiation":"Initiation: 09/25/2020","start_date":" 09/25/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-10-23"}]